Hill-Rom Holdings Inc (NYSE:HRC) had its price target reduced by research analysts at Needham & Company LLC from $93.00 to $90.00 in a research report issued to clients and investors on Monday, November 6th, Marketbeat Ratings reports. The firm presently has a “buy” rating on the medical technology company’s stock. Needham & Company LLC’s price objective would suggest a potential upside of 7.75% from the stock’s previous close.
Other research analysts have also recently issued reports about the company. Zacks Investment Research upgraded Hill-Rom from a “hold” rating to a “buy” rating and set a $90.00 price objective on the stock in a report on Friday, October 27th. KeyCorp reiterated a “buy” rating and issued a $82.00 price objective on shares of Hill-Rom in a report on Tuesday, October 17th. BidaskClub cut Hill-Rom from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 24th. Stifel Nicolaus restated a “buy” rating and set a $84.00 price target on shares of Hill-Rom in a research note on Sunday, July 30th. Finally, Cantor Fitzgerald set a $86.00 price target on Hill-Rom and gave the stock a “hold” rating in a research note on Friday, July 28th. Four research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $88.57.
Hill-Rom (HRC) traded up $0.42 during mid-day trading on Monday, hitting $83.53. The stock had a trading volume of 190,267 shares, compared to its average volume of 523,483. The company has a quick ratio of 1.34, a current ratio of 1.77 and a debt-to-equity ratio of 1.55. The stock has a market capitalization of $5,470.38, a price-to-earnings ratio of 21.53, a PEG ratio of 1.77 and a beta of 1.19. Hill-Rom has a 1-year low of $52.58 and a 1-year high of $84.65.
In related news, SVP Andreas G. Frank sold 3,940 shares of the stock in a transaction on Wednesday, September 13th. The stock was sold at an average price of $77.84, for a total value of $306,689.60. Following the transaction, the senior vice president now owns 16,701 shares of the company’s stock, valued at $1,300,005.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Andreas G. Frank sold 6,870 shares of the stock in a transaction on Thursday, September 14th. The shares were sold at an average price of $77.48, for a total value of $532,287.60. Following the completion of the transaction, the senior vice president now directly owns 16,701 shares in the company, valued at approximately $1,293,993.48. The disclosure for this sale can be found here. 2.20% of the stock is currently owned by corporate insiders.
A number of large investors have recently bought and sold shares of HRC. Wellington Management Group LLP increased its holdings in Hill-Rom by 129.2% in the first quarter. Wellington Management Group LLP now owns 20,776 shares of the medical technology company’s stock valued at $1,467,000 after buying an additional 11,712 shares during the last quarter. Legal & General Group Plc grew its holdings in shares of Hill-Rom by 116.9% during the first quarter. Legal & General Group Plc now owns 42,688 shares of the medical technology company’s stock worth $3,014,000 after purchasing an additional 23,011 shares during the last quarter. State Street Corp grew its holdings in shares of Hill-Rom by 3.4% during the first quarter. State Street Corp now owns 1,637,462 shares of the medical technology company’s stock worth $115,603,000 after purchasing an additional 53,082 shares during the last quarter. Credit Suisse AG grew its holdings in shares of Hill-Rom by 0.5% during the first quarter. Credit Suisse AG now owns 118,010 shares of the medical technology company’s stock worth $8,331,000 after purchasing an additional 576 shares during the last quarter. Finally, Public Employees Retirement System of Ohio grew its holdings in shares of Hill-Rom by 2.8% during the first quarter. Public Employees Retirement System of Ohio now owns 39,419 shares of the medical technology company’s stock worth $2,783,000 after purchasing an additional 1,057 shares during the last quarter. 80.37% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This report was posted by BBNS and is the sole property of of BBNS. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://baseballnewssource.com/markets/hill-rom-holdings-inc-hrc-price-target-lowered-to-90-00-at-needham-company-llc-2/1761914.html.
Hill-Rom Company Profile
Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.
Receive News & Ratings for Hill-Rom Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom Holdings Inc and related companies with our FREE daily email newsletter.